Table 3 Ongoing clinical trials aimed at androgen receptor-positive TNBC
From: Recent advances in therapeutic strategies for triple-negative breast cancer
Drugs | Pharmacological mechanism | Register ID | Phase | Status |
|---|---|---|---|---|
Bicalutamide | AR antagonists | NCT02348281 | II | Terminated |
NCT03055312 | III | Terminated | ||
NCT02353988 | II | Unknown | ||
Enzalutamide | AR pathway inhibitors | NCT02689427 | IIb | Recruiting |
NCT02750358 | II | Active | ||
Seviteronel | A potent CYP17 lyase inhibitor | NCT02130700 | II | Completed |
NCT02580448 | I/II | Completed | ||
MK-2866 | A nonsteroidal selective AR modulator | NCT02368691 | I | Terminated |
Darolutamide | Competitively inhibiting AR binding, translocation, and transcription | NCT03383679 | II | Recruiting |
Dehydroepiandrosterone | Intermediates of steroid hormones | NCT00972023 | I | Terminated |
Orteronel | CYP17 inhibitors | NCT01990209 | II | Active |